APC 2025 Agenda
Thursday April 10, 2025 |
||||
| Updated 3/10/2025 *Speakers and titles are subject to change | ||||
| Session | Speaker | Company | Time | |
| Registration and Coffee | 7:45AM-8:45AM | |||
| Conference Opening | David Ebner | Pfizer | 8:45AM - 8:50AM | |
| Speaker Introduction | Cheng Zhong | Pharmaron | 8:50AM-8:55AM | |
|
PROTAb Platform: An Innovative Universal Linker for DACs with CRBN-Based Degraders |
Teresa Mako | Orum | 8:55AM-9:25AM | |
| Speaker Introduction | Kenneth Boy | BMS | 9:25AM-9:30AM | |
| Drugging MYC mRNA with Small Molecules | Karthik Iyer | Arrakis Therapeutics | 9:30AM-10:00AM | |
| Speaker Introduction | Michael Shultz | Novartis | 10:00AM-10:05AM | |
| Discovery and Optimization of a Series of MALT1 Inhibitors Using Structure-Based Drug Design and Parallel Medicinal Chemistry | Daniel Smaltz | Pfizer | 10:05AM-10:35AM | |
| AM Break | 10:35AM-10:55AM | |||
| Speaker Introduction | Rebecca Casaubon | Triana Bio | 10:55AM-11:00AM | |
| Discovery of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK-Inhibitor for the Treatment of MS | Martin Himmelbauer | Biogen | 11:00AM-11:30AM | |
| Speaker Introduction | Benoit Moreau | Remix Therapeutics | 11:30AM-11:35AM | |
| The First BDK Inhibitor/Degrader Clinical Candidate, PF-07328948, as a Treatment for Heart Failure | Kevin Filipski | Pfizer | 11:35AM-12:05PM | |
| Speaker Introduction | Andy Tsai | Treeline Biosciences | 12:05PM-12:10PM | |
|
Plenary Lecture Chemical Tools for Regulating Reactive Sulfur Species in Redox Biology |
Ming Xian | Brown University | 12:10PM-12:50PM | |
| Lunch | 12:50PM-1:50PM | |||
| Speaker Introduction | Susan Ashwell | Civetta | 1:50PM-1:55PM | |
| Vendor Talk - Exploiting Solvent Exposed Salt-Bridge Interactions for the Discovery of Potent Inhibitors of SOS1 Using Free-Energy Perturbation Simulations | Abba Leffler |  |
1:55PM-2:20PM | |
| Speaker Introduction | Christopher Reimann | AstraZeneca | 2:20PM-2:25PM | |
| DNA Encoded Libraries – Drug Discovery through DEL screening and the Application of On-DNA Binder Confirmation | Mark Mantell | GSK | 2:25PM-2:55PM | |
| Speaker Introduction | Pedro Garcia Barrantes | Vertex | 2:55PM-3:00PM | |
| Discovery of MK-4424: An Exquisitely Selective Potent & CNS-Penetrant RIPK1 Type-III Inhibitor | Brandon Vara | Merck | 3:00PM-3:30PM | |
| PM Break | 3:30PM-3:45PM | |||
| Speaker Introduction | Michael Shultz | Novartis | 3:45PM-3:50PM | |
| Development of a Commercial-Ready Process for TNG908, a Potent, Selective and Brain Penetrant MTA-Cooperative PRMT5 Inhibitor | Colin Liang | Tango Therapeutics | 3:50PM-4:20PM | |
| Plenary Speaker Introduction | Catherine Jorand-Lebrun | Nexo Therapeutics | 4:20PM-4:25PM | |
|
Plenary Lecture Chemical Biology Tools for Measuring Intracellular Drug Delivery |
Joshua Kritzer | Tufts University | 4:25PM-5:05PM | |
| Closing Remarks | Catherine Jorand-Lebrun | Nexo Therapeutics | 5:05PM-5:10PM | |
| Reception | 5:10PM-6:10PM | |||